Evidence map›Paper›PMID 37452281›Full record

Trial reportThe journal of headache and pain2023

Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study).

Licia Grazzi, Domenico D'Amico, Erika Guastafierro, Greta Demichelis, Alessandra Erbetta, Davide Fedeli, Anna Nigri, Emilio Ciusani, Corso Barbara, Alberto Raggi

2 registry-linked trialsAbstract readRandomized Controlled TrialClinical Trial, Phase III
In one paragraph

Trial report in The journal of headache and pain, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03671681 phase4completednot on this map

A Randomized Clinical Trial on the Efficacy and Cost-efficacy of Adding on a Mindfulness-based Therapy to Standard Medical Prophylaxis in the Treatment of Patients With Chronic Migraine Associated to Medication Overuse Following Structured Withdrawal: the Mind-CM Study

TypeinterventionalSponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaRan2018 to 2023Enrolled177ConditionsChronic Migraine, Medication Overuse HeadacheArmsMindfulness, Prophylactic
NCT06938178 recruitingnot on this mapstarted 2024, after this paper: background citation

High-Density EEG-MEG-wearable EEG: Comparison of Quantitative Electroencephalographic Indicators as Neurophysiological Markers of Effectiveness of Mindfulness Therapy in Addition to Standard Treatment in Patients With High-frequency Episodic Migraine

TypeobservationalSponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaRan2024 to 2026Enrolled40ConditionsMigraine, Migraine Disease, High Frequency Episodic MigraineArmsMindfulness treatment
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Cost-efficacy evaluation of a mindfulness-based program added to treatment as usual for the treatment of chronic migraine associated to medication overuse headache.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Trial
  5. Trial
  6. Trial
  7. Article
  8. Psychological interventions for migraine.Nature reviews. Neurology · 2026
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Licia GrazziNeuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Domenico D'AmicoNeuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Erika GuastafierroNeurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milano, Italy.
Greta DemichelisDepartment of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Alessandra ErbettaDepartment of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Davide FedeliDepartment of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Anna NigriDepartment of Neuroradiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Emilio CiusaniDepartment of Diagnostic and Technology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Corso BarbaraNeuroscience Institute, Consiglio Nazionale delle Ricerche, Padova, Italy.
Alberto RaggiNeurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133, Milano, Italy. alberto.raggi@istituto-besta.it.

Funding

Ministero della Salute RF-2016-02364801
6 · The paper itself

Abstract

backgroundMindfulness gained considerable attention for migraine management, but RCTs are lacking. We aimed to assess the efficacy of a six-sessions mindfulness-based treatment added to treatment as usual (TaU) in patients with Chronic Migraine (CM) and Medication Overuse Headache (MOH) on headache frequency, medication intake, quality of life, disability, depression and anxiety, cutaneous allodynia, awareness of inner states, work-related difficulties, and disease cost.

methodsIn this Phase-III single-blind RCT carried out in a specialty Italian headache center, 177 patients with CM and MOH were randomized 1:1 to either TaU (withdrawal from overused drugs, education on proper medication use and lifestyle issues, and tailored prophylaxis) or mindfulness-based intervention added to TaU (TaU + MIND). The mindfulness-based intervention consisted of six group session of mindfulness practice and 7-10 min daily self-practice. The primary endpoint was the achievement of ≥ 50% headache frequency reduction at 12 months compared to baseline, and was analyzed on an intention-to-treat principle using Pearson's Chi-Squared test. Secondary endpoints included medication intake, quality of life (QoL), disability, depression and anxiety, cutaneous allodynia, awareness of inner states, work-related difficulties, and disease cost. The secondary endpoints were analyzed using per-protocol linear mixed models.

resultsOut of the 177 participants 89 were randomized to TaU and 88 to TaU + MIND. Patients in the TaU + MIND group outperformed those in TaU for the primary endpoint (78.4% vs. 48.3%; p < 0.0001), and showed superior improvement in headache frequency, QoL and disability, headache impact, loss of productive time, medication intake, and in total, indirect and direct healthcare costs.

conclusionsA mindfulness-based treatment composed of six-week session and 7-10 min daily self-practice added on to TaU is superior to TaU alone for the treatment of patients with CM and MOH.

trial registrationMIND-CM was registered on clinicaltrials.gov (NCT03671681) on14/09/2018.

Indexed as

Headache Disorders, SecondaryMigraine DisordersMindfulnessHeadacheHumansHyperalgesiaQuality of LifeSingle-Blind MethodTreatment OutcomeChronic MigraineCost of IllnessDisabilityMedication Overuse HeadacheMigraine ProphylaxisMindfulnessQuality of Life

Identifiers

PMID37452281
PMCPMC10347788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.